{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:57:01Z","timestamp":1774400221943,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474134"],"award-info":[{"award-number":["82474134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273785"],"award-info":[{"award-number":["82273785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2026.109534","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:11:21Z","timestamp":1769040681000},"page":"109534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["TRK inhibitors in cancer therapeutics: Recent advances and future perspectives"],"prefix":"10.1016","volume":"170","author":[{"given":"Hong-ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan-hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1473","key":"10.1016\/j.bioorg.2026.109534_bb0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1098\/rstb.2006.1894","article-title":"Neurotrophin-regulated signalling pathways, philosophical transactions of the royal society of London","volume":"361","author":"Reichardt","year":"2006","journal-title":"Series B, Biol. Sci."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109534_bb0010","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-08-0651","article-title":"On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology","volume":"15","author":"Thiele","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109534_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev.neuro.26.041002.131421","article-title":"Selectivity in neurotrophin signaling: theme and variations","volume":"26","author":"Segal","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/ERC-12-0078","article-title":"DUSP6\/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells","volume":"20","author":"Degl\u2019Innocenti","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109534_bb0025","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-10-3034","article-title":"Role and relevance of TrkB mutations and expression in non-small cell lung cancer","volume":"17","author":"Harada","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02706217","article-title":"Expression of the neurotrophin receptors Trk a and Trk B in adult human astrocytoma and glioblastoma","volume":"28","author":"Wadhwa","year":"2003","journal-title":"J. Biosci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion\u2013positive solid tumors: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109534_bb0060","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109534_bb0070","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109534_bb0075","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"7\u20138","key":"10.1016\/j.bioorg.2026.109534_bb0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/13543776.2023.2262136","article-title":"Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update","volume":"33","author":"Jaworski","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.109534_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102733","article-title":"NTRK gene fusion testing and management in lung cancer","volume":"127","author":"Repetto","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"14_Supplement","key":"10.1016\/j.bioorg.2026.109534_bb0095","doi-asserted-by":"crossref","first-page":"2954A","DOI":"10.1158\/1538-7445.AM2016-2954A","article-title":"Abstract 2954A: a potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants","volume":"76","author":"Kozaki","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109534_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152572","article-title":"NTRK-fusions - a new kid on the block","volume":"215","author":"M\u00e4rkl","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109534_bb0105","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-21-0465","article-title":"Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer","volume":"27","author":"Laetsch","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"Suppl_8","key":"10.1016\/j.bioorg.2026.109534_bb0110","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.109534_bb0115","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.3390\/molecules29153560","article-title":"Pyrazolo[1,5-a]pyrimidine as a prominent framework for tropomyosin receptor kinase (Trk) inhibitors-synthetic strategies and SAR insights","volume":"29","author":"Mahajan","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109534_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0959-4388(00)00092-1","article-title":"Neurotrophin signal transduction in the nervous system","volume":"10","author":"Kaplan","year":"2000","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(01)00573-6","article-title":"Neurotrophins: to cleave or not to cleave","volume":"33","author":"Chao","year":"2002","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109534_bb0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","article-title":"trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3","volume":"66","author":"Lamballe","year":"1991","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109534_bb0135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"154","key":"10.1016\/j.bioorg.2026.109534_bb0140","first-page":"195","article-title":"Trk receptor tyrosine kinases in metastasis and cancer therapy","volume":"28","author":"Regua","year":"2019","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bpj.2020.11.2262","article-title":"The biased ligands NGF and NT-3 differentially stabilize Trk-a dimers","volume":"120","author":"Ahmed","year":"2021","journal-title":"Biophys. J."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0150","first-page":"1133","article-title":"The regulatory role of the BDNF\/TrkB pathway in organ and tissue fibrosis","volume":"36","author":"Hang","year":"2021","journal-title":"Histol. Histopathol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbr.2012.03.010","article-title":"Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling","volume":"231","author":"Li","year":"2012","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical Cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0165","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers3010510","article-title":"Nerve growth factor in cancer cell death and survival","volume":"3","author":"Molloy","year":"2011","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41379-020-0623-z","article-title":"Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST)","volume":"34","author":"Atiq","year":"2021","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0180","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s12253-020-00871-7","article-title":"Clinical significance of Trk receptor expression as a new therapeutic target in hepatocellular carcinoma","volume":"26","author":"Choi","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109534_bb0190","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"issue":"33","key":"10.1016\/j.bioorg.2026.109534_bb0195","doi-asserted-by":"crossref","first-page":"55353","DOI":"10.18632\/oncotarget.19512","article-title":"Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient","volume":"8","author":"Milione","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301730","article-title":"Critical domains for NACC2-NTRK2 fusion protein activation","volume":"19","author":"Yang","year":"2024","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109534_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114829","article-title":"ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models","volume":"43","author":"Schmid","year":"2024","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-018-0622-4","article-title":"Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109534_bb0215","first-page":"367","article-title":"NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS, the journal of pathology","volume":"9","author":"Zito Marino","year":"2023","journal-title":"Clin. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-023-00427-3","article-title":"Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China","volume":"7","author":"Xu","year":"2023","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-Centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0230","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1634\/theoncologist.2019-0641","article-title":"Antitumor activity of Larotrectinib in Esophageal carcinoma with NTRK gene amplification","volume":"25","author":"Hempel","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.109534_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-319-91442-8_10","article-title":"Larotrectinib (LOXO-101)","author":"Berger","year":"2018","journal-title":"Small Mol. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0240","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109534_bb0245","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109534_bb0250","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(94)90048-5","article-title":"Functions of the neurotrophins during nervous system development: what the knockouts are teaching us","volume":"77","author":"Snider","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109534_bb0255","doi-asserted-by":"crossref","unstructured":"G.W. Robinson, A.J. Gajjar, K.M. Gauvain, E.M. Basu, M.E. Macy, L.D. Maese, A.J. Sabnis, J.H. Foster, S. Shusterman, J. Yoon, B.D. Weiss, M. Abdelbaki, M. Farid-Kapadia, G. Meneses-Lorente, A. Cardenas, K. Hutchinson, G. Bergthold, E.C. Maneval, E. Fox, A.V. Desai, Phase 1\/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors, J. Clin. Oncol 37 (15_suppl) (2019) 10009.","DOI":"10.1200\/JCO.2019.37.15_suppl.10009"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109534_bb0265","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2019.1538796","article-title":"Larotrectinib for the treatment of TRK fusion solid tumors","volume":"19","author":"Laetsch","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14656566.2021.1876664","article-title":"Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion","volume":"22","author":"Filippi","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0280","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/13543784.2015.1096344","article-title":"Entrectinib: a potent new TRK, ROS1, and ALK inhibitor","volume":"24","author":"Rolfo","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0285","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109534_bb0290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14737140.2020.1747439","article-title":"Entrectinib for the treatment of metastatic NSCLC: safety and efficacy","volume":"20","author":"Sartore-Bianchi","year":"2020","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0295","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0300","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0310","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","article-title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","volume":"31","author":"Demetri","year":"2020","journal-title":"Annals Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.109534_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.04.053","article-title":"Targeting tropomyosin receptor kinase for cancer therapy","volume":"175","author":"Miao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0320","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0325","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.bioorg.2026.109534_bb0330","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109534_bb0335","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/1740774514547397","article-title":"Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding","volume":"11","author":"Thall","year":"2014","journal-title":"Clin. Trials (London, England)"},{"key":"10.1016\/j.bioorg.2026.109534_bb0340","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2018.36.15_suppl.8519","article-title":"Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients","volume":"36","author":"Besse","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109534_bb0345","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-14-1105","article-title":"Altiratinib inhibits tumor growth, invasion, angiogenesis, and mcroenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41416-019-0503-9","article-title":"A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas","volume":"121","author":"Lin","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.bioorg.2026.109534_bb0355","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-20-1630","article-title":"U.S. phase I first-in-human study of taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK inhibitor, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109534_bb0360","doi-asserted-by":"crossref","unstructured":"K. Pal, A. Regina, A. Elagoz, V. Albert, J. Boudreault, M. Ouellet, L. Pilote, N. Bruneau-Latour, H. Wang, L. Tao, E. Bellavance, P. White, S. Ciblat, J. Leef, R. Bishop, EXTH-80. PBI-200: in vivo efficacy of a novel, highly CNS-penetrant next generation TRK inhibitor, Neuro-Oncology 23 (Supplement_6) (2021) vi181-vi182.","DOI":"10.1093\/neuonc\/noab196.719"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109534_bb0365","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109534_bb0370","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-17-0704","article-title":"Fast-TRKing drug development for rare molecular targets","volume":"7","author":"Parikh","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109534_bb0375","unstructured":"N.X. Kong, C. Zhou, Z. Zheng, Heterocyclic compund as TRK inhibitor, WO2020001415A1, 2020-01-02."},{"key":"10.1016\/j.bioorg.2026.109534_bb0380","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.2022.40.16_suppl.3106","article-title":"Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor","volume":"40","author":"Wei","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109534_bb0385","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.2147\/OTT.S177051","article-title":"Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence","volume":"12","author":"Ricciuti","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109534_bb0390","doi-asserted-by":"crossref","first-page":"478","DOI":"10.6004\/jnccn.2021.7022","article-title":"Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib","volume":"19","author":"Florou","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109534_bb0395","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.3390\/cancers15164081","article-title":"Evaluation of systemic treatment options for gastrointestinal stromal tumours","volume":"15","author":"Gol\u010di\u0107","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109534_bb0400","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0405","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.bioorg.2026.109534_bb0415","doi-asserted-by":"crossref","first-page":"15503","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of next-generation tropomyosin receptor kinase inhibitors for combating multiple resistance associated with protein mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109534_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114654","article-title":"Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance","volume":"241","author":"Gong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109534_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115953","article-title":"Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance","volume":"264","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109534_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116640","article-title":"Discovery of novel indazole derivatives as second-generation TRK inhibitors","volume":"276","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109534_bb0435","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.bmcl.2003.12.002","article-title":"Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles","volume":"14","author":"Wood","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0440","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/ml200261d","article-title":"Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models","volume":"3","author":"Albaugh","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0445","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1021\/jm3002982","article-title":"Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities","volume":"55","author":"Hong","year":"2012","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109534_bb0450","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2174\/1570180815666171229151138","article-title":"Molecular docking and 3D-QSAR studies on 7-azaindole derivatives as inhibitors of Trk a: a strategic design in novel anticancer agents","volume":"15","author":"Aouidate","year":"2018","journal-title":"Lett. Drug Des. Discover."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109534_bb0455","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery, optimization, and evaluation of novel pyridin-2(1H)-one analogues as potent TRK inhibitors for cancer treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"Pt 2","key":"10.1016\/j.bioorg.2026.109534_bb0460","article-title":"Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo","volume":"245","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109534_bb0465","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1073\/pnas.1611577114","article-title":"Structural characterization of nonactive site, TrkA-selective kinase inhibitors","volume":"114","author":"Su","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109534_bb0470","unstructured":"M. Tomizawa, H. Nishii, H. Tanaka, M. Aoki, Dihydronaphtho[2,3-b]benzofuran derivative, WO2017073706A1, 2017-05-04."},{"key":"10.1016\/j.bioorg.2026.109534_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114601","article-title":"Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor","volume":"241","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109534_bb0480","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1021\/acs.jmedchem.1c01597","article-title":"Structural optimization and structure\u2013activity relationship studies of 6, 6-dimethyl-4-(phenylamino)-6H-pyrimido [5, 4-b][1, 4] oxazin-7 (8H)-one derivatives as a new class of potent inhibitors of pan-trk and their drug-resistant mutants","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0485","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109534_bb0490","unstructured":"J. Lin, Y. Ying, J. Liao, X. Zhang, Z. Li, J. Yuan, W. Jia, W. Wang, Compound having macrocyclic molecular structure and use thereof, WO2019149131A1, 2019-08-08."},{"key":"10.1016\/j.bioorg.2026.109534_bb0495","unstructured":"J.J. Cui, Y. Li, E.W. Rogers, D. Zhai, J. Ung, Macrocycle kinase inhibitors, ZA201901034B, 2021-06-30."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109534_bb0500","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation pan-TRK kinase inhibitors for the treatment of cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109534_bb0505","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the first highly selective and broadly effective macrocycle-based type II TRK inhibitors that overcome clinically acquired resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109534_bb0510","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1021\/acs.jmedchem.3c00899","article-title":"Structure-based optimization of the third generation type II macrocycle TRK inhibitors with improved activity against solvent-front, xDFG, and gatekeeper mutations","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109534_bb0515","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41698-024-00686-8","article-title":"BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors","volume":"8","author":"Sheng","year":"2024","journal-title":"NPJ. Precis. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109534_bb0520","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/acs.molpharmaceut.9b00673","article-title":"TrkC-targeted kinase inhibitors and PROTACs","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol. Pharm."},{"issue":"23","key":"10.1016\/j.bioorg.2026.109534_bb0525","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","article-title":"Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109534_bb0530","unstructured":"J. Liu, M.B. Plewe, J. Wang, X. Han, L. Chen, Tropomyosin receptor kinase (TRK) degradation compounds and methods of use, WO2020038415A1, 2020-02-27."},{"key":"10.1016\/j.bioorg.2026.109534_bb0535","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109534_bb0540","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1242\/dev.008227","article-title":"Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development","volume":"134","author":"Bartkowska","year":"2007","journal-title":"Development"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:15:53Z","timestamp":1770066953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":108,"alternative-id":["S0045206826000702"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109534","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRK inhibitors in cancer therapeutics: Recent advances and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109534"}}